Denali Therapeutics Inc. (DNLI) Tops Q3 EPS by 1c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.74), $0.01 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Alphabet to replace Verizon in the Dow Jones Industrial Average
• Cboe launches binary options suite tied to Mini-S&P 500 Index